The global threat of antimicrobial resistance: science for intervention

I Roca¹, M Akova², F Baquero³, J Carlet⁴, M Cavaleri⁵, S Coenen⁶, J Cohen⁷, D Findlay⁸, I Gyssens⁹, O E Heuer¹⁰, G Kahlmeter¹¹, H Kruse¹², R Laxminarayan¹³, E Liébana¹⁴, L López-Cerero¹⁵, A MacGowan¹⁶, M Martins¹⁷, J Rodríguez-Baño¹⁸, J-M Rolain¹⁹, C Segovia²⁰, B Sigauque²¹, E Tacconelli²², E Wellington²³, J Vila²⁴

Affiliations

¹ ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
² Department of Medicine, Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey ; ESCMID Executive Committee, Basel, Switzerland.
³ Department of Microbiology at the Ramón y Cajal University Hospital, Ramón y Cajal Institute for Health Research (IRYCIS), Division for Research in Microbial Biology and Evolution, CIBERESP, Madrid, Spain.
⁴ Fondation Hôpital St, Joseph, Paris, France and World Alliance Against Antibiotic Resistance (WAAAR), Creteil, France.
⁵ European Medicines Agency (EMA), London, UK.
⁶ Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
⁷ Brighton and Sussex Medical School, Brighton, UK.
⁸ Global Commercial Lead, GlaxoSmithKline (GSK), London, UK.
⁹ Department of Medicine, Radboud University Medical Center and Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
¹⁰ European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
¹¹ Clinical Microbiology, Central Hospital, Växjö, Sweden ; ESCMID Executive Committee, Basel, Switzerland ; EUCAST Steering Committee, Växjö, Sweden.
¹² WHO Regional Office for Europe, UN City, Marmorvej, Copenhagen, Denmark.
¹³ Center for Disease Dynamics, Economics and Policy, Washington, DC, USA ; Princeton University, Princeton, NJ, USA.
¹⁴ Scientific Unit on Biological Hazards, European Food Safety Authority (EFSA), Parma, Italy.
¹⁵ Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain.
¹⁶ Department of Medical Microbiology, Southmead Hospital, Bristol, UK ; EUCAST Steering Committee, Växjö, Sweden.
¹⁷ School of Public Health, Physiotherapy and Population Science, UCD Centre for Food and Safety, Molecular Innovation and Drug Discovery, University College Dublin, Dublin, Ireland.
¹⁸ Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, and Departamento de Medicina, Universidad de Sevilla, Seville, Spain ; ESCMID Executive Committee, Basel, Switzerland.
¹⁹ Aix-Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), Inserm, IHU Méditerranée Infection, Faculté de Médecine et de Pharmacie, and APHM, CHU Timone, Pôle Infectieux, Marseille, France.
²⁰ Instituto de Salud Carlos III, ISCIII, Madrid, Spain.
²¹ Centro de Investigação em Saúde da Manhiça and Instituto Nacional de Saúde/Ministério de Saúde, Maputo, Mozambique.
²² Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany ; ESCMID Executive Committee, Basel, Switzerland.
²³ School of Life Sciences, University of Warwick, Coventry, UK.
²⁴ ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain ; ESCMID Executive Committee, Basel, Switzerland.

PMID: 26029375
PMCID: PMC4446399
DOI: 10.1016/j.nmni.2015.02.007

Review

The global threat of antimicrobial resistance: science for intervention

I Roca et al. New Microbes New Infect. 2015.

. 2015 Apr 16:6:22-9.

doi: 10.1016/j.nmni.2015.02.007. eCollection 2015 Jul.

Authors

Affiliations

¹ ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
² Department of Medicine, Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey ; ESCMID Executive Committee, Basel, Switzerland.
³ Department of Microbiology at the Ramón y Cajal University Hospital, Ramón y Cajal Institute for Health Research (IRYCIS), Division for Research in Microbial Biology and Evolution, CIBERESP, Madrid, Spain.
⁴ Fondation Hôpital St, Joseph, Paris, France and World Alliance Against Antibiotic Resistance (WAAAR), Creteil, France.
⁵ European Medicines Agency (EMA), London, UK.
⁶ Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
⁷ Brighton and Sussex Medical School, Brighton, UK.
⁸ Global Commercial Lead, GlaxoSmithKline (GSK), London, UK.
⁹ Department of Medicine, Radboud University Medical Center and Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
¹⁰ European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
¹¹ Clinical Microbiology, Central Hospital, Växjö, Sweden ; ESCMID Executive Committee, Basel, Switzerland ; EUCAST Steering Committee, Växjö, Sweden.
¹² WHO Regional Office for Europe, UN City, Marmorvej, Copenhagen, Denmark.
¹³ Center for Disease Dynamics, Economics and Policy, Washington, DC, USA ; Princeton University, Princeton, NJ, USA.
¹⁴ Scientific Unit on Biological Hazards, European Food Safety Authority (EFSA), Parma, Italy.
¹⁵ Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain.
¹⁶ Department of Medical Microbiology, Southmead Hospital, Bristol, UK ; EUCAST Steering Committee, Växjö, Sweden.
¹⁷ School of Public Health, Physiotherapy and Population Science, UCD Centre for Food and Safety, Molecular Innovation and Drug Discovery, University College Dublin, Dublin, Ireland.
¹⁸ Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, and Departamento de Medicina, Universidad de Sevilla, Seville, Spain ; ESCMID Executive Committee, Basel, Switzerland.
¹⁹ Aix-Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), Inserm, IHU Méditerranée Infection, Faculté de Médecine et de Pharmacie, and APHM, CHU Timone, Pôle Infectieux, Marseille, France.
²⁰ Instituto de Salud Carlos III, ISCIII, Madrid, Spain.
²¹ Centro de Investigação em Saúde da Manhiça and Instituto Nacional de Saúde/Ministério de Saúde, Maputo, Mozambique.
²² Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany ; ESCMID Executive Committee, Basel, Switzerland.
²³ School of Life Sciences, University of Warwick, Coventry, UK.
²⁴ ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain ; ESCMID Executive Committee, Basel, Switzerland.

PMID: 26029375
PMCID: PMC4446399
DOI: 10.1016/j.nmni.2015.02.007

Erratum in

Corrigendum to "The global threat of antimicrobial resistance: science for intervention" [New Microbes New Infect 6 (2015): 22-29].
Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, Cohen J, Findlay D, Gyssens I, Heuer OE, Kahlmeter G, Kruse H, Laxminarayan R, Liébana E, López-Cerero L, MacGowan A, Martins M, Rodríguez-Baño J, Rolain JM, Segovia C, Sigauque B, Tacconelli E, Wellington E, Vila J. Roca I, et al. New Microbes New Infect. 2015 Sep 10;8:175. doi: 10.1016/j.nmni.2015.09.004. eCollection 2015 Nov. New Microbes New Infect. 2015. PMID: 27257501 Free PMC article.

Abstract

In the last decade we have witnessed a dramatic increase in the proportion and absolute number of bacterial pathogens resistant to multiple antibacterial agents. Multidrug-resistant bacteria are currently considered as an emergent global disease and a major public health problem. The B-Debate meeting brought together renowned experts representing the main stakeholders (i.e. policy makers, public health authorities, regulatory agencies, pharmaceutical companies and the scientific community at large) to review the global threat of antibiotic resistance and come up with a coordinated set of strategies to fight antimicrobial resistance in a multifaceted approach. We summarize the views of the B-Debate participants regarding the current situation of antimicrobial resistance in animals and the food chain, within the community and the healthcare setting as well as the role of the environment and the development of novel diagnostic and therapeutic strategies, providing expert recommendations to tackle the global threat of antimicrobial resistance.

Keywords: Antibiotic consumption; antibiotic resistance; antibiotic stewardship; antibiotics as growth promoters; drug discovery; infection control measures; multidrug resistant bacteria; self-medication; surveillance; wastewater treatment plants.

PubMed Disclaimer

Figures

**Fig. 1**
Intervention measures to tackle antibiotic resistance. Flow of antibiotic resistance genes, antimicrobial agents and pathogens ultimately generating multidrug-resistant bacteria and reaching a human host. Measures to prevent the emergence and dissemination of antibiotic resistance are shown at different key points.

See this image and copyright information in PMC

References

1. Marshall B.M., Levy S.B. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev. 2011;24:718–733. - PMC - PubMed
1. Liebana E., Carattoli A., Coque T.M., Hasman H., Magiorakos A.P., Mevius D. Public health risks of enterobacterial isolates producing extended-spectrum beta-lactamases or AmpC beta-lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options. Clin Infect Dis. 2013;56:1030–1037. - PubMed
1. European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMEA) 2009. Joint opinion on antimicrobial resistance (AMR) focused on zoonotic infections.http://www.efsa.europa.eu/en/scdocs/doc/1372.pdf Available at: [accessed 8.5.15]
1. World Health Organization . 2011. WHO list of critically important antimicrobials (CIA), 3rd revision.http://www.who.int/foodsafety/publications/antimicrobials-third/en/ Available at: [accessed 8.5.15]
1. Colpan A., Johnston B., Porter S., Clabots C., Anway R., Thao L. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis. 2013;57:1256–1265. - PMC - PubMed

Publication types

Actions

Grants and funding

001/WHO_/World Health Organization/International

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The global threat of antimicrobial resistance: science for intervention

Affiliations

The global threat of antimicrobial resistance: science for intervention

Authors

Affiliations

Erratum in

Abstract

Figures

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical